References
- Abdelgawad IA, Mossallam GI, Radwan NH, et al (2013). Can Glypican3 be diagnostic for early hepatocellular carcinoma among Egyptian patients? Asian Pac J Cancer Prev, 14, 7345-9. https://doi.org/10.7314/APJCP.2013.14.12.7345
- Chan ES, Pawel BR, Corao DA, et al (2013). Immunohistochemical expression of glypican-3 in pediatric tumors, an analysis of 414 cases. Pediatr Dev Pathol, 16, 272-7. https://doi.org/10.2350/12-06-1216-OA.1
- Chu PG, Ishizawa S, Wu E, et al (2002). Hepatocyte antigen as a marker of hepatocellular carcinoma, an immunohistochemical comparison to carcinoembryonic antigen, CD10, and alpha-fetoprotein. Am J Surg Pathol, 26, 978-88. https://doi.org/10.1097/00000478-200208000-00002
- Filmus J, Selleck SB (2001). Glypicans, proteoglycans with a surprise. J Clin Invest, 108, 497-501. https://doi.org/10.1172/JCI200113712
- Grisaru S, Cano-Gauci DF, Tee J, et al (2001). Glypican-3 modulates BMP- and FGF-mediated effects during renal branching morphogenesis. Dev Biol, 231, 31-46. https://doi.org/10.1006/dbio.2000.0127
- Kim YH, Kang JS (2013). Expression of glypican-3 in mouse embryo stem cells and its derived hepatic lineage cells treated with diethylnitrosamine in vitro. Asian Pac J Cancer Prev, 14, 6341-5. https://doi.org/10.7314/APJCP.2013.14.11.6341
- Kong CS, Appenzeller M, Ferrell LD (2000). Utility of CD34 reactivity in evaluating focal nodular hepatocellular lesions sampled by fine needle aspiration biopsy. Acta Cytol, 44, 218-22. https://doi.org/10.1159/000326363
- Hsu HC, Cheng W, Lai PL (1997). Cloning and expression of a developmentally regulated transcript MXR7 in hepatocellular carcinoma, biological significance and temporospatial distribution. Cancer Res, 57, 5179-84.
- Ismail H, Broniszczak D, Kaliciński P, et al (2012). Changing treatment and outcome of children with hepatoblastoma, analysis of a single center experience over the last 20 years. J Pediatr Surg, 47, 1331-9. https://doi.org/10.1016/j.jpedsurg.2011.11.073
- Lage H, Dietel M, Froschle G, et al (1998). Expression of the novel mitoxantrone resistance associated gene MXR7 in colorectal malignancies. Int J Clin Pharmacol Ther, 36, 58-60.
- Lin H, Huber R, Schlessinger D, et al (1999). Frequent silencing of the GPC3 gene in ovarian cancer cell lines. Cancer Res, 59, 807-10.
- Midorikawa Y, Ishikawa S, Iwanari H, et al (2003). Glypican-3, overexpressed in hepatocellular carcinoma, modulates FGF2 and BMP-7 signaling. Int J Cancer, 103, 455-65. https://doi.org/10.1002/ijc.10856
- Murthy SS, Shen T, De Rienzo A, et al (2000). Expression of GPC3, an X-linked recessive overgrowth gene, is silenced in malignant mesothelioma. Oncogene, 19, 410-6. https://doi.org/10.1038/sj.onc.1203322
- Paine-Saunders S, Viviano BL, Zupicich J, et al (2000). Glypican-3 controls cellular responses to Bmp4 in limb patterning and skeletal development. Dev Biol, 225, 179-87. https://doi.org/10.1006/dbio.2000.9831
- Park YN, Yang CP, Fernandez GJ, et al (1998). Neoangiogenesis and sinusoidal 'capillarization' in dysplastic nodules of the liver. Am J Surg Pathol, 22, 656-62. https://doi.org/10.1097/00000478-199806000-00002
- Piscione TD, Phan T, Rosenblum ND (2001). BMP7 controls collecting tubule cell proliferation and apoptosis via Smad1-dependent and -independent pathways. Am J Physiol Renal Physiol, 280, F19-33.
- Saikali Z, Sinnett D (2000). Expression of glypican3 (GPC3) in embryonal tumors. Int J Cancer, 89, 418-22. https://doi.org/10.1002/1097-0215(20000920)89:5<418::AID-IJC4>3.0.CO;2-I
- Watanabe A, Hippo Y, Taniguchi H, et al (2003). An opposing view on WWOX protein function as a tumor suppressor. Cancer Res, 63, 8629-33.
- Wang FH, Wen JM, Vong HT, et al (2013). Glypican 3 expression in hepatoblastoma and its diagnostic implication. Zhonghua Bing Li Xue Za Zhi, 42, 806-9.
- Xiang YY, Ladeda V, Filmus J (2001). Glypican -3 expression is silenced in human breast cancer. Oncogene, 20, 7408-12. https://doi.org/10.1038/sj.onc.1204925
- Yamauchi N, Watanabe A, Hishinuma M, et al (2005). The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma. Mod Pathol, 18, 1591-8.
- Zhang Z, Coomans C, David G (2001). Membrane heparan sulfate proteoglycan-supported FGF2-FGFR1 signaling. Evidence in support of the 'cooperative end structures' model. J Biol Chem, 276, 41921-9. https://doi.org/10.1074/jbc.M106608200
- Zhu ZW, Friess H, Wang L, et al (2001). Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders. Gut, 48, 558-64. https://doi.org/10.1136/gut.48.4.558
- Zynger DL, Gupta A, Luan C, et al (2008). Expression of glypican 3 in hepatoblastoma, an immunohistochemical study of 65 cases. Hum Pathol, 39, 224-30. https://doi.org/10.1016/j.humpath.2007.06.006